Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis

Jee, S.H.; Won, S.Y.; Yun, J.E.; Lee, J.E.; Park, J.S.; Ji, S.S.

doi:10.1016/j.ijgo.2003.08.017

« Previous Next »International Journal of Gynecology & Obstetrics
Volume 85, Issue 3 , Pages 301-308, June 2004

Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis

S.H. Jee
- Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
- Corresponding author. Tel.: +82-2-361-5095; fax: +82-2-365-5118
S.Y. Won
- Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
J.E. Yun
- Department of Epidemiology and Health Promotion, Graduate School of Health Science and Management, Yonsei University, Seoul, South Korea
J.E. Lee
- DNA Link, Inc., Seoul, South Korea
J.S. Park
- Department of Obstetrics and Gynecology, The Catholic University of Korea, Seoul, South Korea
S.S. Ji
- Department of Office Automation, Wonju National College, Wonju, South Korea

Received 19 May 2003; received in revised form 20 August 2003; accepted 27 August 2003.

Abstract

Objectives: Although some studies have reported that the arginine isoform on codon 72 of p53 increases the susceptibility to invasive cervical cancer, such data remain controversial. The objective of this study was to quantitatively summarize the evidence for such a relationship. Methods: Our data sources consisted of a MEDLINE search of the literature published before December 2002, bibliography review, and expert consultation. Thirty-seven studies met the inclusion criteria. Information on sample size, study design, Hardy–Weinberg equilibrium, and method of genotype determination was abstracted by two reviewers using a standardized protocol. The overall odds ratio (OR) of the p53 gene on invasive cervical cancer was estimated using the Mantel–Haenzel method. Results: The overall OR (95% confidence interval) for cervical cancer among those with the homozygous mutant (Arg/Arg) was 1.2 (1.1–1.3, P=0.001) compared with those with the heterozygous mutant (Arg/Pro). By a cellular type of cervical cancer, the overall OR among those with Arg/Arg was statistically significant in adenocarcinomas (1.7, 1.1–2.6, P=0.024), but not in squamous cell carcinomas (1.1, 0.9–1.2, P=0.960), compared with Pro/Pro. Compared with Arg/Pro, the OR among those with Arg/Arg was statistically significant in HPV types 16 (1,5, 1.2–2.0, P=0.002). Conclusions: Overall, the p53 gene was associated with increased risk for invasive cervical cancer. However, the risk varied by country, cellular, and HPV type.

Keywords: Polymorphism, Codon 72 of p53, Cervical cancer